SavedAdd your journal

Journals / Genel Tıp Dergisi / 2011 / Cilt: 21 - Sayı: 4

New options of chronic hepatitis C treatment

Kronik hepatit C tedavisinde yeni seçenekler

Neşe DEMİRTÜRK
Pages
163–168
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: According to data obtained from the literature, protease inhibitors are promises new hope for relapser or nonresponder CHC patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Chronic hepatitis C (CHC) is one of the important reasons of cirrhosis and hepatocellular carcinoma in the world.
📊
Key Findings & Data:Now, pegile-interferon 2a/2b and ribavirin combination is standard treatment for CHC.
💡
Conclusion & Impact:Conclusion: According to data obtained from the literature, protease inhibitors are promises new hope for relapser or nonresponder CHC patients.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Chronic hepatitis C (CHC) is one of the important reasons of cirrhosis and hepatocellular carcinoma in the world. CHC patients should determine because of treatment of them may be prevent cirrhosis and hepatocellular carcinoma. Now, pegile-interferon 2a/2b and ribavirin combination is standard treatment for CHC. In this review treatment options for relapser or nonresponder CHC patients were evaluated. Main findings: Treatment in nonresponder or relapser patients is difficult due to absent of alternative certain treatment. But recently, new developed protease inhibitors may be new option for them. Telaprevir and boceprevir are two important new protease inhibitors. Conclusion: According to data obtained from the literature, protease inhibitors are promises new hope for relapser or nonresponder CHC patients.

Özet

Amaç: Kronik hepatit C (KHC) infeksiyonu tüm dünyada siroz ve karaciğer kanserinin en önemli nedenlerinden biridir. Hastaların tespit edilerek tedavi edilmesi bu olumsuz sonuçların ortaya çıkmasını büyük ölçüde önlemektedir. Günümüzde KHC tedavisinde önerilen standart tedavi şeması, pegile-interferon alfa 2a/2b ile birlikte ribavirin kombinasyonundan oluşmaktadır. Yanıtsız hastalarda yeni tedavi seçenekleri gündemdedir. Bu yazıda özellikle yanıtsız ve relaps gelişen hastalardaki tedavi seçeneklerinin değerlendirilmesi amaçlanmıştır. Ana bulgular: Tedaviye yanıt alınamayan ya da relaps gelişen hastalar için, yeni geliştirilen proteaz inhibitörü ilaçlar içinde telaprevir ve boceprevir ön plana çıkan iki ilaçtır. Sonuç: İncelenen son literatür verilerine göre yanıtsız ya da relaps gelişen KHC hastaları için proteaz inhibitörlerini içeren tedavi kombinasyonları yeni umutlar vaad etmektedir.

🔖

Cite This Article

DEMİRTÜRK, N. (2011). New options of chronic hepatitis C treatment. Genel Tıp Dergisi, Cilt: 21 - Sayı: 4, 163–168. https://ajindex.com/articles/224878

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Pearlman BL, Sjogren MH. Treatment options for HCV nonresponders and relaps patients. Gastroenterol Hepatol 2010;6:1-12
  2. European Association fort he Study of the Liver. EASL clinical practice guidelines: Management of hepatitis C virus infection. J Hepatol 2011; 55:245-64
  3. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011;8:257-64
  4. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterol 2010;138:116-22
  5. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R et al. Randomized study of peginterferonalpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterol 2010;138:108-15
  6. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
  7. Saltoğlu N. Önceki tedaviye yanıtsız/relaps kronik hepatit C hastalarında tedavi ve alternatif tedaviler. Tabak F, Balık İ (ed). Viral Hepatit 2009, 1 baskı, İstanbul Medikal Yayıncılık 2009; 137-150
  8. Patullo V, Heathcote EJ, Wong DKH. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatol Int 2010;4:723-31
  9. Moucari R, Ripault MP, Martinot-Peignoux M, Voitot H, Cardoso AC, Stern C et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009;58:1662-9
  10. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriquez CM et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterol 2005;128:636-41
  11. Huang JF, Dai CY, Hwang SJ, Ho CK, Hsiao PJ, Hsieh MY et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological imolication. Am J Gastroenterol 2007;102:1237-1243
  12. Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC et al. Insulin resistance predicts response to peginterferonalpha/ ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009;50:712-8
  13. Villa E, Karampatou A, Camma C, Di Leo A, Luongo M, Ferrari A